Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1601-1605

  Reddy, Bharathi V ^a   Grossman, Eric J ^a   Trevino, Sharon A ^a   Hursting, Marcie J ^b   Murray, Patrick T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Clinical Science Consulting   (United States)

Author keywords

Anticoagulation; Argatroban; Dialysis; Renal replacement therapy

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN; THROMBIN INHIBITOR;

ADULT; AGED; ANTICOAGULATION; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG REEXPOSURE; DRUG SAFETY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 25844453561     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G033     Document Type: Review

References (25)

1. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7. DOI 10.1016/S0002-9343(96)00258-6
3. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
4. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56. DOI 10.1001/archinte.163.15.1849
5. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
6. Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998;89: 115-22. DOI 10.1016/S0049-3848(97)00301-0
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004;126(suppl):311S-37S.
8. Prescribing information. Refludan [lepirudin (rDNA) for injection]. Wayne, NJ: Berlex Laboratories, October 2002.
9. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29. DOI 10.1592/phco.20.4.318.34881
10. Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1998;52:165-71. DOI 10.1016/0049-3848(88)90095-3
11. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005;39:231-6. Epub 4 Jan 2005. DOI 10.1345/aph.1E480
12. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002;57:177-84. DOI 10.1002/ccd.10276
13. Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003;18:1623-30. DOI 10.1093/ndt/gfg320
14. Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004;66: 2446-53. DOI 10.1111/j.1523-1755.2004.66022.x
15. Shmuely H, Pitlik S, Drucker M, Samra Z, Konisberger H, Leibovici L. Prediction of mortality in patients with bacteremia: the importance of pre-existing renal insufficiency. Ren Fail 2000;22:99-108. DOI 10.1081/JDI-100100856
16. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:970-5. Epub 21 May 2003. DOI 10.1345/aph.1C443
17. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003:37:652-4. Epub 25 Mar 2003. DOI 10.1345/aph.1C187
18. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-14. DOI 10.1592/phco.24.4.409.33168
19. Walenga JM, Ahmad S, Hoppensteadt DA, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-5. DOI 10.1016/S0049-3848(02)00049-X
20. Schwab SJ, Onorato JJ, Sharar LR, Dennis PA. Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987;83:405-10. DOI 10.1016/0002-9343(87)90748-0
21. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-8.
22. Redden D, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J 2003; 145:586-94. DOI 10.1067/mhj.2003.168
23. Zusman RM, Rubin RH, Cata AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981;304:934-9.
24. Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004;61:134-43.
25. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis 1987;9:235-6.